Is Thrombolysis Useful for Acute Stroke Patients? The Experience of the MAST-I Study

  • The MAST-I Collaborative Group


Experimental and physiopathological studies suggest that reperfusion may be useful to prevent the extension of brain infarction if performed in a reasonable period of time after ischemic insult. Thrombolytic agents recanalize myocardial and cerebral vessels, but it is not yet known if they are able to reperfuse brain ischemic tissue. There is some experimental evidence in animals of their efficacy, but it is still uncertain if these agents are able to reduce the size of brain infarct and improve clinical outcome in man.


Acute Stroke Acute Ischemic Stroke Thrombolytic Therapy Thrombolytic Agent Recombinant Tissue Plasminogen Activator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The MAST-I Collaborative Group (1993) Thrombolytic and antithrombotic therapy in acute ischemic stroke. Multicenter Acute Stroke Trial—Italy (MAST-I) In: del Zoppo GJ. Mori E, Hacke W (eds) Thrombolytic therapy in acute ischemic stroke II. Springer, Berlin, pp 86–94Google Scholar
  2. 2.
    Flechter AP, Alkjaersig N, Smyrniotis FE, Sherry S (1958) The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 71: 287–296Google Scholar
  3. 3.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (1990) GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 336: 65–71Google Scholar
  4. 4.
    The International Study Group (1990) In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction. Lancet 336: 71–75CrossRefGoogle Scholar
  5. 5.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 339: 753–70CrossRefGoogle Scholar
  6. 6.
    The GUSTO Angiographie Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329: 1615–1622CrossRefGoogle Scholar
  7. 7.
    Meyer JS, Gilroy J, Barnhart MI (1963) Therapeutic thrombolysis in cerebral thromboemholism. Neurology 13: 927–937PubMedGoogle Scholar
  8. 8.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360Google Scholar
  9. 9.
    Sandercock P, and International Stroke Trial Collaborative Group (1994) International Stroke Trial (IST) Two-week mortality in different categories of patients. Cerebrovasc Dis 4: 221CrossRefGoogle Scholar
  10. 10.
    del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86PubMedCrossRefGoogle Scholar
  11. 11.
    Candelise L, Pinardi G, Aritzu E, Musicco M (1994) Telephone interview for stroke outcome assessment. Cerebrovasc Dis 4: 341–343CrossRefGoogle Scholar
  12. 12.
    Lau J, Antamm EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327: 248–254PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • The MAST-I Collaborative Group

There are no affiliations available

Personalised recommendations